• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Associations between decreases in adiposity and reductions in HbA1c and insulin use in the Look AHEAD cohort.“展望”队列中肥胖程度降低与糖化血红蛋白水平降低及胰岛素使用减少之间的关联。
Obesity (Silver Spring). 2025 Mar;33(3):612-620. doi: 10.1002/oby.24242. Epub 2025 Feb 4.
2
Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes.胰岛素治疗患者起始治疗时按体重指数类别划分的体重增加情况:2型糖尿病患者真实世界数据的新证据
Diabetes Obes Metab. 2016 Dec;18(12):1244-1252. doi: 10.1111/dom.12761. Epub 2016 Sep 21.
3
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.利拉鲁肽 3.0 毫克治疗合并 2 型糖尿病的超重或肥胖患者的疗效和安全性:SCALE 胰岛素随机对照试验。
Diabetes Care. 2020 May;43(5):1085-1093. doi: 10.2337/dc19-1745. Epub 2020 Mar 5.
4
Waist Circumference and its Changes Are More Strongly Associated with the Risk of Type 2 Diabetes than Body Mass Index and Changes in Body Weight in Chinese Adults.在中国成年人中,腰围及其变化与2型糖尿病风险的关联比体重指数和体重变化更为密切。
J Nutr. 2020 May 1;150(5):1259-1265. doi: 10.1093/jn/nxaa014.
5
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.二甲双胍联合胰岛素治疗超重/肥胖 1 型糖尿病青少年的血糖控制效果:一项随机临床试验。
JAMA. 2015 Dec 1;314(21):2241-50. doi: 10.1001/jama.2015.16174.
6
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.在 DUAL V 随机试验中,德谷胰岛素/利拉鲁肽(IDegLira)在一系列不同的血糖异常和身体质量指数类别中均具有疗效。
Diabetes Obes Metab. 2018 Jan;20(1):200-205. doi: 10.1111/dom.13043. Epub 2017 Jul 31.
7
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.恩格列净可降低2型糖尿病患者的体重及脂肪分布指标。
Diab Vasc Dis Res. 2016 Mar;13(2):119-26. doi: 10.1177/1479164115616901.
8
Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.在意大利真实临床环境中接受利拉鲁肽治疗的大量糖尿病患者中,基线特征与临床结局之间的相关性。
Clin Ther. 2015 Mar 1;37(3):574-84. doi: 10.1016/j.clinthera.2014.11.015. Epub 2015 Jan 24.
9
Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.利拉鲁肽对内脏脂肪肥胖、食欲和食物偏好的短期影响:一项针对日本 2 型糖尿病肥胖患者的初步研究。
Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.
10
Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?2 型糖尿病的体重和血糖控制:起始胰岛素治疗的结局如何?
Diabetes Obes Metab. 2011 Sep;13(9):823-31. doi: 10.1111/j.1463-1326.2011.01413.x.

引用本文的文献

1
Association Between Changes in Body Composition and Physical Function After Intensive Behavioral Weight-loss Intervention: A Look AHEAD Trial Subgroup Analysis.强化行为减肥干预后身体成分变化与身体功能之间的关联:“展望”试验亚组分析
J Gerontol A Biol Sci Med Sci. 2025 Jun 10;80(7). doi: 10.1093/gerona/glaf103.

本文引用的文献

1
5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study.英国减肥维持持续支持随机糖尿病缓解临床试验(DiRECT)的 5 年随访:一项扩展研究。
Lancet Diabetes Endocrinol. 2024 Apr;12(4):233-246. doi: 10.1016/S2213-8587(23)00385-6. Epub 2024 Feb 26.
2
Translation of a Diabetes Remission Service into Australian Primary Care: Findings from the Evaluation of DiRECT-Australia.将糖尿病缓解服务转化为澳大利亚初级保健服务:来自 DiRECT-Australia 评估的结果。
J Diabetes Res. 2024 Feb 8;2024:2350551. doi: 10.1155/2024/2350551. eCollection 2024.
3
Introduction and Methodology: Standards of Care in Diabetes-2023.引言与方法:2023年糖尿病护理标准
Diabetes Care. 2023 Jan 1;46(Suppl 1):S1-S4. doi: 10.2337/dc23-Sint.
4
Why does obesity cause diabetes?肥胖为什么会导致糖尿病?
Cell Metab. 2022 Jan 4;34(1):11-20. doi: 10.1016/j.cmet.2021.12.012.
5
Does Lifestyle Intervention Improve Health of Adults with Overweight/Obesity and Type 2 Diabetes? Findings from the Look AHEAD Randomized Trial.生活方式干预是否能改善超重/肥胖和 2 型糖尿病成人的健康?来自 LOOK AHEAD 随机试验的结果。
Obesity (Silver Spring). 2021 Aug;29(8):1246-1258. doi: 10.1002/oby.23158. Epub 2021 May 14.
6
Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.2 型糖尿病患者体成分测量的基线和纵向变化与心力衰竭和心肌梗死风险的关联:来自 LOOK AHEAD 试验的结果。
Circulation. 2020 Dec 22;142(25):2420-2430. doi: 10.1161/CIRCULATIONAHA.120.050941. Epub 2020 Nov 9.
7
Sex differences in metabolic regulation and diabetes susceptibility.性别差异与代谢调控和糖尿病易感性。
Diabetologia. 2020 Mar;63(3):453-461. doi: 10.1007/s00125-019-05040-3. Epub 2019 Nov 21.
8
Mechanisms of Insulin Action and Insulin Resistance.胰岛素作用机制和胰岛素抵抗。
Physiol Rev. 2018 Oct 1;98(4):2133-2223. doi: 10.1152/physrev.00063.2017.
9
Obesity Pharmacotherapy in Patients With Type 2 Diabetes.2型糖尿病患者的肥胖药物治疗
Diabetes Spectr. 2017 Nov;30(4):250-257. doi: 10.2337/ds17-0044.
10
The Look AHEAD Trial: Translating Lessons Learned Into Clinical Practice and Further Study.“展望”试验:将经验教训转化为临床实践与进一步研究
Diabetes Spectr. 2017 Aug;30(3):166-170. doi: 10.2337/ds17-0016.

“展望”队列中肥胖程度降低与糖化血红蛋白水平降低及胰岛素使用减少之间的关联。

Associations between decreases in adiposity and reductions in HbA1c and insulin use in the Look AHEAD cohort.

作者信息

Palmer Rebecca, Neiberg Rebecca H, Beavers Kristen M, Kahn Steven E, Houston Denise K, Wagenknecht Lynne, Johnson Karen C, Pownall Henry J, Espeland Mark A

机构信息

Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

出版信息

Obesity (Silver Spring). 2025 Mar;33(3):612-620. doi: 10.1002/oby.24242. Epub 2025 Feb 4.

DOI:10.1002/oby.24242
PMID:39904719
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11897852/
Abstract

OBJECTIVE

The objective of this study was to elucidate associations between adiposity reduction and changes in HbA1c and insulin use among adults with type 2 diabetes and overweight or obesity.

METHODS

Changes in BMI, waist circumference, and total percent fat mass were obtained over 8 years among 1316 individuals (aged 45-76 years) enrolled in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss. Generalized linear models were used to assess relationships between 5% decreases in adiposity measures with glycated hemoglobin (HbA1c) and insulin use over time.

RESULTS

A 5% reduction in total percent fat was associated with 0.15% (95% CI: 0.12%-0.18%) lower mean HbA1c. Similarly, 5% reductions in waist circumference and BMI were also associated with slightly lower mean HbA1c: 0.16% (95% CI: 0.13%-0.19%) and 0.13% (95% CI: 0.11%-0.16%), respectively. These reductions were associated with lower odds of insulin use over time, ranging from 21% lower odds for a 5% reduction in percent body fat to 32% lower odds for 5% reductions in waist circumference and BMI. Associations were evident across subgroups defined by sex, diabetes duration, obesity status, and intervention assignment.

CONCLUSIONS

Reductions in adiposity are associated with stabilized and slightly lower HbA1c and a marked reduction in the need for insulin therapy. These benefits generalize across clinical subgroups.

摘要

目的

本研究的目的是阐明2型糖尿病合并超重或肥胖的成年人中,体重减轻与糖化血红蛋白(HbA1c)及胰岛素使用变化之间的关联。

方法

在参加糖尿病健康行动(Look AHEAD)减肥临床试验的1316名个体(年龄45 - 76岁)中,获取了8年期间体重指数(BMI)、腰围和体脂总量百分比的变化情况。使用广义线性模型评估体脂测量指标降低5%与糖化血红蛋白(HbA1c)及随时间推移胰岛素使用之间的关系。

结果

体脂总量百分比降低5%与平均HbA1c降低0.15%(95%置信区间:0.12% - 0.18%)相关。同样,腰围和BMI降低5%也与平均HbA1c略有降低相关:分别为0.16%(95%置信区间:0.13% - 0.19%)和0.13%(95%置信区间:0.11% - 0.16%)。这些降低与随时间推移胰岛素使用几率降低相关,从体脂百分比降低5%时胰岛素使用几率降低21%到腰围和BMI降低5%时胰岛素使用几率降低32%不等。在按性别、糖尿病病程、肥胖状态和干预分配定义的亚组中,关联均很明显。

结论

体重减轻与HbA1c稳定且略有降低以及胰岛素治疗需求显著减少相关。这些益处适用于各个临床亚组。